In addition, GXNT intervention altered the composition of fecal BAs and regulated BA metabolism by mediating the hepatic farnesoid X receptor (FXR)/small heterodimer partner (SHP) and intestinal FXR/fibroblast growth factor 15 (FGF15) axis.<h4>Conclusion</h4>GXNT improved hyperlipidemia by altering the gut microbiota and regulating BA metabolism in HFD-fed mice. The gene discussed is NR1H4; the disease is hyperlipidemia.